Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Lung Cancer | Research

Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer

Authors: Atsushi Kagimoto, Yasuhiro Tsutani, Kei Kushitani, Takahiro Kambara, Takahiro Mimae, Yoshihiro Miyata, Yukio Takeshima, Morihito Okada

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Acute exacerbation (AE) of interstitial pneumonia (IP) is the most fatal complication after lung resection for lung cancer. To improve the prognosis of lung cancer with IP, the risk factors of AE of IP after lung resection should be assessed. S100 calcium-binding protein A4 (S100A4) is a member of the S100 family of proteins and is a known marker of tissue fibrosis. We examined the usefulness of S100A4 in predicting AE of IP after lung resection for lung cancer.

Methods

This study included 162 patients with IP findings on preoperative high-resolution computed tomography scan who underwent curative-intent lung resection for primary lung cancer between April 2007 and March 2019. Serum samples were collected preoperatively. Resected lung tissue from 76 patients exhibited usual IP (UIP) pattern in resected lung were performed immunohistochemistry (IHC). Relationship between S100A4 and the incidence of AE of IP and short-term mortality was analyzed.

Results

The receiver operating characteristic area under the curve for serum S100A4 to predict postoperative AE of IP was 0.871 (95% confidence interval [CI], 0.799–0.943; P < 0.001), with a sensitivity of 93.8% and a specificity of 75.3% at the cutoff value of 17.13 ng/mL. Multivariable analysis revealed that a high serum S100A4 level (> 17.13 ng/mL) was a significant risk factor for AE of IP (odds ratio, 42.28; 95% CI, 3.98–449.29; P = 0.002). A 1-year overall survival (OS) was significantly shorter in patients with high serum levels of S100A4 (75.3%) than in those with low serum levels (92.3%; P = 0.003). IHC staining revealed that fibroblasts, lymphocytes, and macrophages expressed S100A4 in the UIP area, and the stroma and fibrosis in the primary tumor expressed S100A4, whereas tumor cells did not.

Conclusions

Serum S100A4 had a high predictive value for postoperative AE of IP and short-term mortality after lung resection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5–8.CrossRef Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5–8.CrossRef
2.
go back to reference Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17:1216–9.CrossRef Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17:1216–9.CrossRef
3.
go back to reference Sato T, Watanabe A, Kondo H, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung disease. J Thorac Cardiovasc Surg. 2015;149:64–9.CrossRef Sato T, Watanabe A, Kondo H, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung disease. J Thorac Cardiovasc Surg. 2015;149:64–9.CrossRef
4.
go back to reference Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2013;61:578–607.CrossRef Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2013;61:578–607.CrossRef
5.
go back to reference Watanabe A, Miyajima M, Mishina T, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg. 2013;61:254–61.CrossRef Watanabe A, Miyajima M, Mishina T, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg. 2013;61:254–61.CrossRef
6.
go back to reference Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cadiovasc Surg. 2014;147:1604–11.CrossRef Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cadiovasc Surg. 2014;147:1604–11.CrossRef
10.
go back to reference Akiyama N, Hozumi H, Isayama T, et al. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. Respirology. 2020;25:743–9.CrossRef Akiyama N, Hozumi H, Isayama T, et al. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. Respirology. 2020;25:743–9.CrossRef
11.
go back to reference Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef
12.
go back to reference Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRef Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRef
13.
go back to reference Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Hybrid surgical approach of video-assisted minithoracotomy for lung cancer: significance of direct visualization on quality of surgery. Chest. 2005;128:2696–701.CrossRef Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Hybrid surgical approach of video-assisted minithoracotomy for lung cancer: significance of direct visualization on quality of surgery. Chest. 2005;128:2696–701.CrossRef
14.
go back to reference Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications; five-year experience. Ann Surg. 2009;250:187–96.CrossRef Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications; five-year experience. Ann Surg. 2009;250:187–96.CrossRef
15.
go back to reference Ohsawa M, Tsutani Y, Fujiwara M, Mimae T, Miyata Y, Okada M. Predicting severe postoperative complication in patients with lung cancer and interstitial pneumonia. Ann Thorac Surg. 2020;109:1054–60.CrossRef Ohsawa M, Tsutani Y, Fujiwara M, Mimae T, Miyata Y, Okada M. Predicting severe postoperative complication in patients with lung cancer and interstitial pneumonia. Ann Thorac Surg. 2020;109:1054–60.CrossRef
16.
go back to reference Sato T, Kondo H, Watanabe A, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg. 2015;63:164–72.CrossRef Sato T, Kondo H, Watanabe A, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg. 2015;63:164–72.CrossRef
17.
go back to reference Tsutani Y, Mimura T, Kai Y, et al. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. 2017;154:1089–96.CrossRef Tsutani Y, Mimura T, Kai Y, et al. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. 2017;154:1089–96.CrossRef
18.
go back to reference Oh SY, Kim MY, Kim JE, et al. Evolving early lung cancers detected during follow-up of idiopathic interstitial pneumonia: serial CT features. Am J Roentgenol. 2015;204:1190–6.CrossRef Oh SY, Kim MY, Kim JE, et al. Evolving early lung cancers detected during follow-up of idiopathic interstitial pneumonia: serial CT features. Am J Roentgenol. 2015;204:1190–6.CrossRef
19.
go back to reference Xia H, Bodempudi V, Benyumov A, et al. Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis. Am J Pathol. 2014;184:1369–83.CrossRef Xia H, Bodempudi V, Benyumov A, et al. Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis. Am J Pathol. 2014;184:1369–83.CrossRef
20.
go back to reference Xia H, Gilbertsen A, Herrera J, et al. Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis. J Clin Invest. 2017;12:2586–97.CrossRef Xia H, Gilbertsen A, Herrera J, et al. Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis. J Clin Invest. 2017;12:2586–97.CrossRef
21.
go back to reference Li Z, Li Y, Liu S, Qin Z. Extracellular S100A4 as a key player in fibrotic diseases. J Cell Mol Med. 2020;24:5973–83.CrossRef Li Z, Li Y, Liu S, Qin Z. Extracellular S100A4 as a key player in fibrotic diseases. J Cell Mol Med. 2020;24:5973–83.CrossRef
22.
go back to reference Zhang H, Liu J, Yue D, et al. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 2013;66:937–45.CrossRef Zhang H, Liu J, Yue D, et al. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 2013;66:937–45.CrossRef
23.
go back to reference Miyazaki N, Abe Y, Oida Y, et al. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression. Int J Oncol. 2006;28:1369–74.PubMed Miyazaki N, Abe Y, Oida Y, et al. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression. Int J Oncol. 2006;28:1369–74.PubMed
24.
go back to reference Sack U, Walther W, Scudiero D, et al. Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018–36.CrossRef Sack U, Walther W, Scudiero D, et al. Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018–36.CrossRef
25.
go back to reference Cadamuro M, Spagnuolo G, Sambado L, et al. Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016;76:4775–84.CrossRef Cadamuro M, Spagnuolo G, Sambado L, et al. Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016;76:4775–84.CrossRef
26.
go back to reference Tanaka K, Tsutani Y, Wakabayashi M, et al. Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol. 2020;50:1076–9.CrossRef Tanaka K, Tsutani Y, Wakabayashi M, et al. Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol. 2020;50:1076–9.CrossRef
Metadata
Title
Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer
Authors
Atsushi Kagimoto
Yasuhiro Tsutani
Kei Kushitani
Takahiro Kambara
Takahiro Mimae
Yoshihiro Miyata
Yukio Takeshima
Morihito Okada
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01554-y

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.